The CFO receives options on 410,000 shares with a $0.30 exercise price at aTyr Pharma (ATYR).
aTyr Pharma's CFO, Brandon Yaras, was granted an employee stock option award for 410,000 shares of common stock. The options have an exercise price of $0.30 per share and will vest in 48 equal monthly installments starting November 1, 2026, becoming fully exercisable by November 1, 2030. This insider transaction was filed on October 1, 2026, and also includes provisions for accelerated vesting under certain conditions.
Operating cash flow per share of aTyr Pharma, Inc. – HAN:471A
The article focuses on the operating cash flow per share of aTyr Pharma, Inc., traded on the Hannover Stock Exchange under the ticker HAN:471A. It presents a specific financial metric for the company, indicating the value and changes over a period. The content primarily serves as a financial data point without further analysis or commentary.
aTyr Pharma, Inc. Statistics – HAN:471A
This article provides a detailed overview of aTyr Pharma, Inc.'s financial statistics, traded on the Hannover Stock Exchange under the ticker 471A. It lists various key financial stats and ratios, including current key stats, valuation ratios, profitability ratios, liquidity ratios, solvency ratios, and per-share metrics, with data points spanning from 2012 to 2025. The page serves as a hub for investors to analyze the company's market capitalization, P/E ratio, EPS, and ROI.
Total operating expenses of aTyr Pharma, Inc. – HAN:471A
This article provides financial information for aTyr Pharma, Inc. (HAN:471A), specifically focusing on its total operating expenses. The data is presented through TradingView, integrating market data from ICE Data Services and reference data from FactSet.
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
ATyr Pharma (NASDAQ: ATYR) has secured FDA alignment for its Phase 3 study protocol of efzofitimod, a therapeutic candidate for pulmonary sarcoidosis. The company plans to initiate study activities in Q4 2026 across the U.S. and Europe, with the trial designed to assess the safety and effectiveness of efzofitimod over 54 weeks. ATyr Pharma has also streamlined its operations, reducing its workforce by 60% and trimming its pipeline to focus resources on efzofitimod, although it will require additional capital for the Phase 3 development.
aTyr Pharma Reaches FDA Protocol Agreement for Efzofitimod Phase 3 Trial
aTyr Pharma has secured an FDA agreement on the protocol for its Efzofitimod Phase 3 trial, targeting patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. This crucial alignment before study initiation helps prevent mid-trial disruptions. The company plans to submit regulatory applications in both the U.S. and Europe in Q4 2026, aiming for a global trial and potential simultaneous review.
aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
aTyr Pharma announced that it has aligned with the FDA on the plans for its Phase 3 study of efzofitimod for the treatment of pulmonary sarcoidosis. The company's announcement indicates progress in its clinical development program for this therapeutic candidate. The full article content is behind a paywall.
ATYR Looks 27.8% Undervalued on GF Value™ as Phase 3 Trial Frame
aTyr Pharma (NASDAQ: ATYR) announced FDA agreement on the design framework for its pivotal Phase 3 clinical trial of efzofitimod for pulmonary sarcoidosis. Despite a high Price-to-Sales ratio and ongoing unprofitability, GuruFocus’ GF Value™ suggests the stock is modestly undervalued by 27.8%. Insider and guru buying activity indicates confidence, though the company faces significant financial risks and weak profitability.
aTyr Pharma reports FDA alignment on sarcoidosis Phase 3
aTyr Pharma announced that the FDA has aligned with its proposed 372-patient Phase 3 trial protocol for efzofitimod in pulmonary sarcoidosis. The new study will focus on lung function as its primary endpoint, a shift from a previous trial that missed its steroid reduction endpoint. However, aTyr Pharma stated it needs additional capital to fund the planned Phase 3 trial, which is expected to begin study-related activities in Q4 2026.
Why is aTyr Pharma stock surging today?
aTyr Pharma's stock surged nearly 9.8% after reaching an agreement with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of efzofitimod for chronic, symptomatic pulmonary sarcoidosis. The company plans to initiate study-related activities in Q4 2026, though it acknowledged that additional financing will be required for the Phase 3 program. This regulatory alignment has provided investors with renewed confidence despite a challenging broader market.
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma has announced that it has reached alignment with the FDA on the protocol for a global Phase 3 study of its lead therapeutic candidate, efzofitimod, for patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The study will evaluate the efficacy and safety of efzofitimod using forced vital capacity (FVC) as the primary endpoint and is expected to enroll approximately 372 patients. The company anticipates initiating study-related activities in the fourth quarter of 2026 and will need additional capital for future development.
FDA and aTyr align on a planned lung disease drug trial for up to about 372 patients.
aTyr Pharma announced that it has reached alignment with the FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, for pulmonary sarcoidosis. The global study aims to enroll up to 372 patients and will evaluate the efficacy and safety of efzofitimod over 54 weeks, with the primary endpoint being the change in forced vital capacity (FVC). The company expects to initiate study-related activities in the fourth quarter of 2026 and will require additional capital for further development.
aTyr Pharma Jumps 5% After FDA Signs Off on Phase 3 Trial Design for Lung Disease Drug
aTyr Pharma saw its shares rise by 5% after reaching a formal agreement with the FDA on the Phase 3 trial design for efzofitimod, its lead drug candidate for pulmonary sarcoidosis. The 54-week study will enroll up to 372 patients, comparing efzofitimod against a placebo, with the primary endpoint being the change in forced vital capacity. The company acknowledged it needs to secure additional capital to fund the Phase 3 program, despite holding $58.9 million in cash as of June 30, which it expects to last into late 2028.
aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial
aTyr Pharma (NASDAQ:ATYR) has announced FDA alignment on the protocol for its phase 3 study of efzofitimod, a treatment for chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company plans to begin study activities in Q4 2026 and will seek additional capital to fund the global, randomized, double-blind, placebo-controlled trial. The study will evaluate efzofitimod's efficacy and safety over 54 weeks, enrolling up to 372 patients.
aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial By Investing.com
aTyr Pharma has reached an agreement with the FDA on the protocol for a phase 3 study of efzofitimod for chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company plans to initiate study activities in Q4 2026 and will seek additional capital to fund the trial, which aims to enroll approximately 372 patients. The study's primary endpoint will be the change in forced vital capacity at week 48, supported by positive data from a previous subgroup analysis.
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
aTyr Pharma has secured FDA alignment on the protocol for its global Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis, planning to begin study-related activities in Q4 2026. The 54-week trial will enroll up to 372 patients, comparing efzofitimod to placebo, with the primary endpoint being the change in forced vital capacity at week 48. The company acknowledges that additional capital will be required through financing, grants, partnerships, or licensing to fund the development.
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma announced that it has reached alignment with the FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The global study will evaluate efzofitimod with FVC as the primary endpoint and is expected to initiate study-related activities in the fourth quarter of 2026. The company believes efzofitimod has the potential to become an important new treatment option given the limited alternatives for these patients.
aTyr Pharma (NASDAQ: ATYR) Schedules October 16 Vote on Reverse Stock Split Between 1-for-10 and 1-for-50
aTyr Pharma (NASDAQ: ATYR) will hold a special meeting on October 16, 2026, for shareholders to vote on a reverse stock split with a ratio between 1-for-10 and 1-for-50. The purpose of this action is to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. The board of directors will ultimately determine the exact ratio and whether to proceed with the split, pending shareholder approval, but warns that sustaining the stock price above the threshold is not guaranteed.
aTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis Study
aTyr Pharma announced an update on the FDA's response timing for its planned Phase 3 study of efzofitimod for chronic pulmonary sarcoidosis, anticipating feedback by mid-September 2026. The study will be a global, randomized, double-blind, placebo-controlled trial evaluating efzofitimod's efficacy and safety in up to 372 patients with moderate to severe pulmonary sarcoidosis. The primary endpoint will measure the change in forced vital capacity at week 48.
FDA response expected by mid-September for aTyr’s lung disease trial
aTyr Pharma announced that it expects to receive U.S. FDA feedback on the protocol for its planned Phase 3 study of efzofitimod for chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease by mid-September 2026. The planned 54-week global trial aims to enroll approximately 372 patients, evaluating efzofitimod's efficacy and safety with primary and secondary endpoints focused on lung function and patient-reported outcomes. This update follows the company's submission of the protocol in June 2026 and provides crucial timing for the next stage of clinical development.
aTyr Pharma (Nasdaq:ATYR) - analisi del titolo
aTyr Pharma is a clinical-stage biotechnology company focusing on therapies for fibrosis and inflammation, with its lead candidate efzofitimod in Phase 3 clinical trials for pulmonary sarcoidosis and Phase 2 for systemic sclerosis-related ILD. The company faces significant financial risks, including low revenue, high cash burn, unprofitability, and substantial shareholder dilution, leading to a recent Nasdaq deficiency notice for its stock trading below $1.00. Despite these challenges, there have been recent positive updates regarding efzofitimod's clinical development and a CFO transition.
aTyr Pharma And 2 Other Penny Stocks With Promising Potential
This article identifies aTyr Pharma, INmune Bio, and Nu Skin Enterprises as penny stocks with promising potential, despite current financial challenges. It highlights their innovative therapies and strategic advancements, emphasizing the importance of strong balance sheets and fundamental potential in a volatile market. The report also provides a brief overview of each company's financial health and market position.
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III
Freedom Broker analysts have maintained a "Buy" rating on aTyr Pharma (ATYR) shares with a $3.50 price target, suggesting a 536% upside from the current price. The key catalyst is the FDA's expected comments by the end of August on the protocol for a new Phase III study of efzofitimod for pulmonary sarcoidosis. Despite the potential, analysts note the investment remains high-risk, requiring a new Phase III trial and additional funding.
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1
Wells Fargo has reaffirmed its Hold rating for ATyr Pharma (ATYR.US) and maintained its price target at $1. This indicates that Wells Fargo believes the stock will perform in line with the market.
aTyr, Biogen, City name legal chiefs
Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their operations. The new legal chiefs bring extensive experience in the biopharmaceutical and biotechnology industries to their respective roles.
Why is aTyr Pharma stock gaining today?
aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors are reacting positively to the extended cash runway, upcoming FDA feedback on a Phase 3 protocol, and completed enrollment in a Phase 2 study.
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its primary endpoint in a previous trial. The restructuring is expected to save $13 million annually and extend the cash runway into late 2028, though additional capital will still be needed.
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025
Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage, prior to a negative study announcement that caused a significant stock price drop.
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to help patients taper steroid usage. The stock price dropped significantly after the company announced its EFZO-FIT study did not meet its primary endpoint.
ATyr Pharma Announces Second Quarter 2026 Res
This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced its second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease (ILD). The company reduced its workforce by approximately 60% and is focusing resources on advancing efzofitimod, a novel biologic immunomodulator for ILD, in anticipation of FDA feedback on its planned Phase 3 study in pulmonary sarcoidosis. The restructuring is expected to reduce annualized operating expenses by about $13 million, extending the company's cash runway into late 2028.
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary
aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its primary endpoint, and has implemented an operational restructuring including a 60% workforce reduction to conserve cash. aTyr Pharma is also advancing its preclinical candidate ATYR0101 and expanding its tRNA synthetase discovery platform.
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD
aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial lung disease (ILD). They have completed enrollment for a Phase 2 study in SSc-ILD and are awaiting FDA feedback on a Phase 3 protocol for pulmonary sarcoidosis.
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus
aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing for FDA feedback on its Phase 3 pulmonary sarcoidosis study protocol. The stock is considered modestly overvalued by GuruFocus's GF Value™ and has a low GF Score™ of 18/100, though insider buying and stable guru ownership provide some positive signals.
aTyr Pharma cuts 60% of workforce after Q2 results
aTyr Pharma (ATYR) announced a 60% workforce reduction and corporate restructuring following its Q2 2026 results to prioritize its efzofitimod program. The company reported a net loss of $10.3 million and expects its current cash of $58.9 million to fund operations into late 2028. Key executive changes were also announced, with a planned Phase 3 study protocol submitted to the FDA and Phase 2 topline results expected in Q1 2027.
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The company's stock price dropped significantly after it announced that its EFZO-FIT study did not meet its primary endpoint on September 15, 2025.
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD
aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate, efzofitimod, for interstitial lung disease (ILD). They have completed enrollment for their Phase 2 SSc-ILD study and are awaiting FDA feedback on a submitted Phase 3 protocol for pulmonary sarcoidosis, with topline results for the Phase 2 study expected in Q1 2027.
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced its second-quarter 2026 results and a corporate restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung disease (ILD). The company is awaiting FDA feedback by the end of August 2026 on its planned Phase 3 study protocol for pulmonary sarcoidosis and expects topline results from the Phase 2 EFZO-CONNECT™ study in SSc-ILD in the first quarter of 2027. This strategic shift aims to conserve capital and extend its cash runway into late 2028.
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced its second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program for interstitial lung disease (ILD). The company reduced its workforce by approximately 60% and enacted other cost-saving measures to focus resources on its lead asset, efzofitimod, as it awaits FDA feedback on a planned Phase 3 study in pulmonary sarcoidosis. Enrollment for the Phase 2 EFZO-CONNECT™ study in SSc-ILD is complete, with topline results expected in Q1 2027, and the company projects its cash reserves to last into late 2028.
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 - Contact Levi & Korsinsky
A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. The stock price dropped significantly after aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in one day.
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership
FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power over all 2,471,418 shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares, reflecting her control over FMR-related entities.
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 – Contact Levi & Korsinsky
Levi & Korsinsky is alerting shareholders of aTyr Pharma, Inc. (ATYR) to protect their rights in a class action securities lawsuit. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to completely taper steroid usage. This led to a significant stock price decline after the EFZO-FIT study failed to meet its primary endpoint, resulting in an 83.2% drop in one day.
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The stock price dropped significantly after the company announced that a key study did not meet its primary endpoint, causing an 83.2% decline in one day.
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations – Contact Levi & Korsinsky Today
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid usage. This news follows a significant 83.2% stock price drop on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn
MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.
aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview
aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.
aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis
aTyr Pharma Inc (ATYR) currently holds a financial score of 6.87, ranking 190 out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The report highlights that relevant financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company, making a comprehensive analysis challenging. The company's stock closed at $0.483, experiencing a -2.17% decrease.
ATYR|aTyr Pharma Inc|Price:0.499|Chg%:+0.010
This article presents a comprehensive stock analysis of aTyr Pharma Inc (ATYR) by TradingKey, highlighting its fundamental stability, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals and institutional confidence. Analysts have rated ATYR as a "Buy" with a significant upside potential, although the stock price is expected to trend down in the medium term.
aTyr Pharma Inc (ATYR) Institutional Confidence
The article details the institutional confidence score for aTyr Pharma Inc (ATYR), which is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. It highlights a 24.02% quarter-over-quarter decrease in institutional shareholding proportion to 56.72%. The largest institutional shareholder is James Simons, holding 0.04% of shares outstanding, with a 3.15% decrease in holdings.
